Checkpoint inhibitors synergize with therapeutic platforms, ZVex™ and GLAAS™ by enhancing lentiviral vector-induced tumor-specific immunity and adjuvant-mediated anti-tumor efficacy
Crossref DOI link: https://doi.org/10.1186/2051-1426-3-S2-P346
Published Online: 2015-11-04
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Albershardt, Tina C
Parsons, Andrea J
ter Meulen, Jan
Berglund, Peter
Article History
First Online: 4 November 2015